Elicio Therapeutics, Inc.
General ticker "ELTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $136.7M (TTM average)
Elicio Therapeutics, Inc. follows the US Stock Market performance with the rate: 38.6%.
Estimated limits based on current volatility of 4.4%: low 9.96$, high 10.87$
Factors to consider:
- Earnings expected soon, date: 2026-05-12 bmo
- Total employees count: 32 as of 2024
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.74$, 12.32$]
- 2026-12-31 to 2027-12-31 estimated range: [3.73$, 10.12$]
Financial Metrics affecting the ELTX estimates:
- Negative: with PPE of -3.1 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -30.15 <= 0.07
- Positive: Investing cash flow per share per price, % of -0.01 > -0.65
- Negative: Shareholder equity ratio, % of 6.33 <= 19.49
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0.92 <= 3.29
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term ELTX quotes
Long-term ELTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $35.74MM | $44.99MM | $37.71MM |
| Operating Income | $-35.74MM | $-44.99MM | $-37.71MM |
| Non-Operating Income | $0.55MM | $-6.91MM | $-1.86MM |
| Interest Expense | $1.06MM | $0.46MM | $1.13MM |
| R&D Expense | $22.68MM | $33.66MM | $24.90MM |
| Income(Loss) | $-35.20MM | $-51.90MM | $-39.57MM |
| Profit(Loss)* | $-35.20MM | $-51.90MM | $-39.57MM |
| Stockholders Equity | $11.37MM | $-11.31MM | $1.64MM |
| Assets | $27.15MM | $28.18MM | $25.86MM |
| Operating Cash Flow | $-32.69MM | $-37.07MM | $-36.95MM |
| Capital expenditure | $0.07MM | $0.09MM | $0.02MM |
| Investing Cash Flow | $-0.03MM | $-0.08MM | $-0.02MM |
| Financing Cash Flow | $38.61MM | $42.32MM | $36.70MM |
| Earnings Per Share** | $-6.96 | $-4.25 | $-2.58 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.